Interferon-α as a treatment modality for colchicine-resistant familial Mediterranean fever

Journal of Rheumatology

Volumn 35, Issue 7, 2008, Pages 1362-1365

  Tweezer Zaks, Nurit ^a   Rabinovich, Einat ^a   Lidar, Merav ^a   Livneh, Avi ^a  

^a HELLER INSTITUTE OF MEDICAL RESEARCH   (Israel)

Author keywords

Colchicine; Familial Mediterranean fever; Interferon ; Treatment

Indexed keywords

COLCHICINE; PARACETAMOL; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ARTHRALGIA; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FAMILIAL MEDITERRANEAN FEVER; FATIGUE; FEVER; HEADACHE; HUMAN; MALAISE; MYALGIA; NAUSEA; PAIN; PHENOTYPE; PRIORITY JOURNAL; QUESTIONNAIRE; SOMNOLENCE;

ADULT; COLCHICINE; FAMILIAL MEDITERRANEAN FEVER; GOUT SUPPRESSANTS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; MIDDLE AGED; PILOT PROJECTS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 47349101976     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Zemer D, Revach M, Pras M, et al. A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. N Engl J Med 1974;291:932-4.
2. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986;314:1001-6.
3. Lidar M, Scherrmann JM, Shinar Y, et al. Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic and socioeconomic characterization. Semin Arthritis Rheum 2004;33:273-82.
4. Amital H, Ben Chetrit E. Therapeutic approaches to familial Mediterranean fever. What do we know and where are we going to? Clin Exp Rheumatol 2004;22 Suppl:S4-7.
5. Tankurt E, Tunca M, Akbaylar H, Gonen O. Resolving familial Mediterranean fever attacks with interferon alpha. Br J Rheumtol 1996;35:1188-9.
6. Tunca M, Tankurt E, Akbaylar Akpinar H, Akar S, Hizli N, Gonen O. The efficacy of interferon alpha on colchicine-resistant familial Mediterranean fever attacks: a pilot study. Br J Rheumatol 1997;36:1005-8.
7. Tunca M, Akar S, Soyturk M, et al. The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: A double blind, placebo controlled trial. Clin Exp Rheumatol 2004;22 Suppl:S37-40.
8. Calguneri M, Apras S, Ozbalkan Z, Ozturk MA, Ertenli I, Kiraz S. The efficacy of continuous interferon alpha administration as an adjunctive agent to colchicine-resistant familial Mediterranean fever patients. Clin Exp Rheumtol 2004;22 Suppl:S41-4.
9. Ureten K, Calguneri M, Onat AM, Ozcakar L, Ertenli I, Kiraz S. Interferon alpha in protracted arthritis of familial Mediterranean fever: a robust alternative for synovectomy. Ann Rheum Dis 2004;63:1527.
10. Kotone-Miyahara Y, Takaori-Kondo A, Fukunaga K, et al. E148Q/M694I mutation in 3 Japanese patients with familial Mediterranean fever. Int J Hematol 2004;79:235-7.
11. Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthitis Rheum 1997;40:1879-85.
12. Pras E, Livneh A, Balow JE Jr, et al. Clinical differences between North African and Iraqi Jews with familial Mediterranean fever. Am J Med Genet 1998;75:216-9.
13. Centola M, Wood G, Frucht DM, et al. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 2000;95:3223-31.
14. Notarnicola C, Didelot MN, Koné-Paut I, Seguret F, Demaille J, Touitou I. Reduced MEFV messenger RNA expression in patients with familial Mediterranean fever. Arthritis Rheum 2002;46:2785-93.
15. Ustek D, Ekmekci CG, Selçukbiricik F, et al. Association between reduced levels of MEFV messenger RNA in peripheral blood leukocytes and acute inflammation. Arthritis Rheum 2007;56:345-50.
16. Shiohara M, Taniguchi S, Masumoto J, et al. ASC, which is composed of a PYD and a CARD, is up regulated by inflammation and apoptosis in human neutrophils. Biochem Biophys Res Commun 2002;293:1314-18.
17. Koklu S, Ozturk MA, Balci M, Yuksel O, Ertenli I, Kiraz S. Interferon-gamma levels in familial Mediterranean fever. Joint Bone Spine 2005;72:38-40.
18. Lidar M, Yaqubov M, Zaks N, Ben-Horin S, Langevitz P, Livneh A. The prodrome: a prominent yet overlooked pre-attack manifestation of familial Mediterranean fever. J Rheumatol 2006;33:1089-92.